Capital Fund Management (CFM)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Capital Fund Management (CFM)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$45.3M	Sell	354,500 -220,900	-38%	-$27.6M	0.2%	94
2025 Q4	$70.2M	Sell	575,400 -526,700	-48%	-$60.4M	0.19%	98
2025 Q3	$110M	Sell	1,102,100 -571,900	-34%	-$51.5M	0.29%	49
2025 Q2	$139M	Buy	1,674,000 +538,500	+47%	+$43M	0.38%	23
2025 Q1	$92.1M	Buy	1,135,500 +569,800	+101%	+$50.9M	0.27%	79
2024 Q4	$50.9M	Buy	565,700 +64,300	+13%	+$6.23M	0.13%	223
2024 Q3	$49.5M	Sell	501,400 -689,900	-58%	-$67.8M	0.14%	206
2024 Q2	$110M	Buy	1,191,300 +25,400	+2%	+$2.28M	0.32%	71
2024 Q1	$111M	Sell	1,165,900 -526,200	-31%	-$48.8M	0.32%	52
2023 Q4	$151M	Buy	1,692,100 +1,188,000	+236%	+$88.2M	0.41%	32
2023 Q3	$36.8M	Buy	504,100 +251,000	+99%	+$20M	0.13%	205
2023 Q2	$21.1M	Buy	253,100 +76,100	+43%	+$6.36M	0.09%	318
2023 Q1	$13.5M	Buy	177,000 +63,300	+56%	+$5.25M	0.06%	400
2022 Q4	$9.44M	Sell	113,700 -126,100	-53%	-$10.2M	0.06%	430
2022 Q3	$19M	Sell	239,800 -33,700	-12%	-$2.84M	0.15%	174
2022 Q2	$20.3M	Buy	273,500 +7,800	+3%	+$586K	0.18%	134
2022 Q1	$23.9M	Buy	265,700 +149,700	+129%	+$13.8M	0.2%	130
2021 Q4	$13M	Buy	116,000 +42,500	+58%	+$5.13M	0.09%	291
2021 Q3	$9.24M	Sell	73,500 -26,500	-27%	-$3.41M	0.07%	379
2021 Q2	$13.5M	Sell	100,000 -28,800	-22%	-$3.79M	0.11%	238
2021 Q1	$17.5M	Buy	128,800 +59,600	+86%	+$8.92M	0.19%	140
2020 Q4	$9.74M	Sell	69,200 -182,200	-72%	-$23.3M	0.09%	261
2020 Q3	$28M	Buy	251,400 +120,700	+92%	+$13.5M	0.35%	76
2020 Q2	$14.6M	Buy	130,700 +87,600	+203%	+$8.63M	0.23%	124
2020 Q1	$3.34M	Sell	43,100 -12,500	-22%	-$1.11M	0.05%	395
2019 Q4	$5.29M	Buy	55,600 +37,600	+209%	+$3.25M	0.04%	518
2019 Q3	$1.37M	Sell	18,000 -26,500	-60%	-$2.2M	0.01%	912
2019 Q2	$3.9M	Sell	44,500 -4,500	-9%	-$384K	0.04%	595
2019 Q1	$4.44M	Sell	49,000 -154,900	-76%	-$13.2M	0.04%	532
2018 Q4	$14.6M	Buy	+203,900	New	+$16.4M	0.13%	212
2018 Q1	–	Sell	-38,100	Closed	-$3.23M	–	2223
2017 Q4	$3.23M	Sell	38,100 -29,100	-43%	-$2.44M	0.02%	819
2017 Q3	$5.82M	Buy	67,200 +49,500	+280%	+$3.97M	0.04%	501
2017 Q2	$1.37M	Buy	+17,700	New	+$1.26M	0.01%	824
2017 Q1	–	Sell	-14,400	Closed	-$852K	–	1875
2016 Q4	$852K	Sell	14,400 -7,400	-34%	-$457K	0.01%	1074
2016 Q3	$1.45M	Sell	21,800 -67,300	-76%	-$4.16M	0.01%	854
2016 Q2	$4.82M	Sell	89,100 -164,500	-65%	-$9.01M	0.05%	452
2016 Q1	$13.1M	Buy	253,600 +166,500	+191%	+$8.65M	0.13%	201
2015 Q4	$6.1M	Sell	87,100 -63,800	-42%	-$4.35M	0.06%	396
2015 Q3	$9.39M	Buy	150,900 +65,700	+77%	+$5.18M	0.11%	252
2015 Q2	$7.16M	Buy	+85,200	New	+$6.63M	0.09%	300
2015 Q1	–	Sell	-3,900	Closed	-$243K	–	1773
2014 Q4	$243K	Buy	+3,900	New	+$222K	﹤0.01%	1433

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Capital Fund Management (CFM)'s XBI Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2025, closing a stake of 19,838 shares — an estimated $1.79M sold.

Capital Fund Management (CFM) first reported a position in XBI in Q2 2014 and held it in 30 quarters. The position peaked at $48.1M in Q3 2023. 656 funds tracked by Wall St. Rank hold XBI as of Q3 2025.

Capital Fund Management (CFM) reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2025 after selling out during the quarter.
Capital Fund Management (CFM) sold 19,838 State Street SPDR S&P Biotech ETF shares in Q3 2025, an estimated $1.79M.
Capital Fund Management (CFM) first reported a position in State Street SPDR S&P Biotech ETF in Q2 2014 and held it in 30 quarters.
Capital Fund Management (CFM)'s State Street SPDR S&P Biotech ETF position peaked at $48.1M in Q3 2023.
656 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.